(Q45855897)

English

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

scientific article published on September 10, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Katalin Boér

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

István Láng

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

Antonio Llombart-Cussac

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

Inger Andreasson

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

Nick Sanders

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

Elizabeth Murray

8

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

Guillermo L. Vivanco

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830502

10 July 2024

Gillian M. Pover

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20830502

10 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20830502

10 July 2024

publication date

10 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

full work available at URL

https://link.springer.com/content/pdf/10.1007/s10637-010-9538-8.pdf

Portable Document Format

1 reference

10.1007/S10637-010-9538-8

https://api.crossref.org/works/10.1007/S10637-010-9538-8

10 July 2024

https://link.springer.com/article/10.1007/s10637-010-9538-8/fulltext.html

1 reference

10.1007/S10637-010-9538-8

https://api.crossref.org/works/10.1007/S10637-010-9538-8

10 July 2024

http://link.springer.com/content/pdf/10.1007/s10637-010-9538-8

1 reference

10.1007/S10637-010-9538-8

https://api.crossref.org/works/10.1007/S10637-010-9538-8

10 July 2024

https://link.springer.com/content/pdf/10.1007/s10637-010-9538-8.pdf

Portable Document Format

1 reference

10.1007/S10637-010-9538-8

https://api.crossref.org/works/10.1007/S10637-010-9538-8

10 July 2024

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

30

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

681-687

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

https://scigraph.springernature.com/pub.10.1007/s10637-010-9538-8

0 references

Prognostic value of vascular endothelial growth factor in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

RET and neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

Design issues of randomized phase II trials and a proposal for phase II screening trials

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

Analysis of progression-free survival in oncology trials: some common statistical issues

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9538-8

21 January 2018

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients*

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human p

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20830502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endocrine Reviews

7

13

3

author name string

JG Klijn

publication date

1992

1 reference

10.1007/S10637-010-9538-8

https://api.crossref.org/works/10.1007/S10637-010-9538-8

10 July 2024

Identifiers

10.1007/S10637-010-9538-8

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/20830502

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45855897&oldid=2200231094"